GWS
VRTX icon

Greykasell Wealth Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Greykasell Wealth Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21K Buy
47
+38
+422% +$17.7K 0.01% 327
2025
Q4 		$4.08K Hold
9
– – ﹤0.01% 421
2025
Q3 		$3.52K Buy
+9
New +$3.76K ﹤0.01% 351

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Greykasell Wealth Strategies's VRTX Position: Q1 2026 in Review

Greykasell Wealth Strategies increased its Vertex Pharmaceuticals (VRTX) stake by 422% in Q1 2026, buying an estimated $17.7K and bringing the position to 47 shares worth $21K. The position accounts for 0.01% of the portfolio, ranked #327.

Greykasell Wealth Strategies first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Greykasell Wealth Strategies held 47 shares of Vertex Pharmaceuticals worth $21K as of Q1 2026.
  • Greykasell Wealth Strategies bought 38 Vertex Pharmaceuticals shares in Q1 2026, an estimated $17.7K.
  • Vertex Pharmaceuticals made up 0.01% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #327 holding.
  • Greykasell Wealth Strategies first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.